Natural killer cells license dendritic cell cross-presentation of B lymphoma cell-associated antigens

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8763-8772

  Dao, Tao ^a   Gomez Nunez, Marta ^a   Antczak, Christophe ^a   Kappel, Barry ^a   Jaggi, Jaspreet Singh ^a   Korontsvit, Tatyana ^a   Zakhaleva, Victoriya ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; B CELL LYMPHOMA; CELL STIMULATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOMA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, BLOCKING; ANTIGENS, CD56; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; PHAGOCYTOSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 29344462755     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0975     Document Type: Article

References (59)

1. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6.
2. van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. Curr Opin Hematol 2004;11:419-25.
3. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
4. Cambell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-33.
5. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
6. Cao W, Myers-Powell BA, Braciale TJ. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 1994; 179:195-202.
7. Bae J, Martinson JA, Klingemann HG. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res 2005;11:1629-38.
8. Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 2002;99:3748-55.
9. + T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005;11:370-9.
10. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998;19: 368-73.
11. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-8.
12. Staerz UD, Krasuyama H, Garner AM. Cytotoxic T lymphocytes against a soluble protein. Nature 1987; 329:449-51.
13. den-Hann JM, Bevan JM. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 2002;196:817-27.
14. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Hardy CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-62.
15. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-hematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
16. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-87.
17. + T cells. J Exp Med 2003;197:985-95.
18. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
19. den-Hann JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000;192:1685-96.
20. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2002;98:8809-14.
21. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88.
22. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cells biology for the active immunotherapy for cancer. Blood 2004;104:2235-44.
23. + T cell tolerance. Immunity 2003;18:713-20.
24. Steinman RM, Hawiger D, Nuzzenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
25. Inaba K, Turley S, Yamaide F. et al. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. J Exp Med 1998;188:2163-73.
26. Adams S, O'Neill D, Bhardwaj N. Maturation matters: importance of maturation for anti-tumor immunity of dendritic cell vaccines. J Clin Oncol 2004;22:3834-5.
27. Jonuleit H, Uhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27: 3135-42.
28. Steinman RM, Nussenzweig MC. Avoiding horrow autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002;99:351-8.
29. + T cells. Nat Immunol 2001;2:1010-7.
30. Itano AA, McSorley SJ, Reinhardt RL, et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003;19:47-57.
31. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004; 21:733-41.
32. Bonifaz L, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199:815-24.
33. Datta SK, Redecke V, Prilliman KR, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003;170:4102-10.
34. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
35. + T cell immunity. Nat Immunol 2004;5:1143-8.
36. + T cell populations lacking helper function. Nat Immunol 2005;2:163-70.
37. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1099-115.
38. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
39. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol 2002;3:6-8.
40. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-51.
41. Fernandez NC, Lozier A, Flament P, et al. Dendritic cells directly trigger NK cell function: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
42. + Tcell effector function in response to an intracellular pathogen. J Immunol 2004;172:130-7.
43. Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005; 42(4):535-9.
44. + T lymphocytes. Leukemia 2002;16:2400-7.
45. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct antigen presentation in allogeneic graft-host interactions in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-9.
46. Ferdynand JK, Engleman EG. Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 1995;155:578-84.
47. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
48. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-95.
49. Akiyama K, Ebihara S, Yada A, et al. Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumor by dendritic cells. J Immunol 2003;170:1641-8.
50. Berard F, Blanco J, Davoust E, et al. Cross-priming naïve CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000;192:1535-44.
51. Henry F, Boisteau L, Bretaudeau B, Lieubeau B, Meflah K, Gregoir M. Antigen-presenting cells that phagocytosed apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-32.
52. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I low targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19:561-9.
53. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195:335-41.
54. Gerosa F, Baldani-Guerra, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
55. Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70: 281-312.
56. Son YI, Dallal RB, Mailliard S, Egawa S, Jonak ZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-12 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res 2001;61: 884-8.
57. Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-9.
58. Mailliard RB, Wankowicz-kalinska A, Cai Q, et al. α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-7.
59. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol 2004;6:107-13.